Loading clinical trials...

Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade | Clinical Trials | Clareo Health

COMPLETEDNA

Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade

NCT01822132•Oregon Health and Science University

Summary

The purpose of this protocol is to learn more about impulsive decision making in people who use methamphetamines. The investigators would like to know if a medication called naltrexone changes how people make decisions. The investigators would also like to know whether changes in decision making can be observed by MRI (magnetic resonance imaging). The research is conducted in Portland, OR.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnostic and Statistical Manual (DSM)-IV Methamphetamine Dependence
•Deemed healthy enough to participate by study physician
•Age 18-55
•Right handed
•English-speaking

Exclusion Criteria

•Current opioid use in the last 30 days; opioid abuse or dependence within past 5 years
•Pregnancy
•MRI contraindications (e.g. metal in head).
•The research is conducted in Portland, OR.

Locations (2)

Oregon Health & Science University

Portland, Oregon, United States

Portland VA Medical Center

Portland, Oregon, United States

Key Dates

Start Date

May 1, 2013

Primary Completion Date

March 1, 2015

Completion Date

March 1, 2015

Last Updated

March 5, 2019

Enrollment

ACTUAL participants

Conditions

Methamphetamine AbuseHIV

Interventions

Extended release naltrexone

DRUG

Placebo

DRUG

Thinking and Memory Problems in People With HIV

NCT01875588

HIV Positive

View study

RECRUITINGPHASE3

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

NCT07071623

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis

View study

RECRUITINGPHASE2

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 5, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade

Inclusion Criteria

Exclusion Criteria

Thinking and Memory Problems in People With HIV

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption